| Withdrawn | An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclata Renal Impairment, End-stage Renal Disease | Phase 2 | 2015-05-01 |
| Completed | Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Human Immunodeficiency Virus Type 1 | Phase 3 | 2015-03-01 |
| Completed | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hep Chronic Hepatitis C, Genotype 4 Chronic Hepatitis C | Phase 3 | 2015-01-01 |
| Completed | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonav Healthy | Phase 1 | 2014-02-01 |
| Completed | A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclat Hepatitis C, Chronic | Phase 2 | 2013-12-12 |
| Completed | A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Inf Respiratory Syncytial Virus | — | 2013-12-01 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-admin Healthy | Phase 1 | 2013-10-01 |
| Completed | An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepa Hepatitis C, Chronic | Phase 3 | 2012-11-01 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 Chronic Hepatitis C | Phase 2 | 2012-10-01 |
| Completed | A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Sin Healthy Male Participants | Phase 1 | 2012-10-01 |
| Completed | A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants Healthy Participants | Phase 1 | 2012-10-01 |
| Terminated | Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity Chronic Hepatitis C Infection | Phase 1 | 2012-08-01 |
| Completed | A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Par Healthy Participants | Phase 1 | 2012-07-01 |
| Terminated | A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Dos Chronic Hepatitis C Infection | Phase 1 | 2012-05-25 |
| Completed | Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir Hepatitis C | Phase 1 | 2012-04-01 |
| Completed | A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted C Healthy Participants | Phase 1 | 2012-04-01 |
| Completed | A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants Healthy | Phase 1 | 2012-04-01 |
| Completed | A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasy Hepatitis C | Phase 3 | 2012-03-27 |
| Completed | A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435. Healthy Volunteers | Phase 1 | 2012-03-01 |
| Completed | TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF Hepatitis C | Phase 3 | 2012-02-01 |
| Completed | A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin Healthy | Phase 1 | 2012-01-01 |
| Completed | A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Hepatitis C | Phase 2 | 2012-01-01 |
| Completed | A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Inf Hepatitis C | Phase 3 | 2011-12-01 |
| Completed | A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Sin Hepatitis C Virus Infection | Phase 1 | 2011-11-01 |
| Completed | A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pe Hepatitis C Virus Genotype-1 | Phase 3 | 2011-10-01 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination W Human Immunodeficiency Virus (HIV) Infection | Phase 4 | 2011-09-01 |
| Completed | 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepa Hepatitis C | Phase 3 | 2011-07-04 |
| Completed | An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Part Hepatitis C | Phase 3 | 2011-03-01 |
| Completed | An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed Hepatitis C | Phase 3 | 2011-02-01 |
| Completed | An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Pati Hepatitis C | Phase 3 | 2011-02-01 |
| Completed | A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Vi HIV-1 Infection | Phase 3 | 2011-02-01 |
| Completed | TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) Whe HIV Infections, Acquired Immunodeficiency Syndrome | Phase 2 | 2009-08-01 |